Antibiotics, Personalized Medicine Partnering Terms and Industry Agreements Reports

DALLAS, January 8, 2015 /PRNewswire/ --

RnRMarketResearch.com adds Partnering Terms and Agreements reports for Personalized Medicine and Antibiotics industries to the pharmaceuticals and healthcare market intelligence collection of its online business research and data library.

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the world's leading healthcare companies. Trends in antibiotics partnering deals, Disclosed headlines, upfronts, milestones and royalties by stage of development, Antibiotics partnering contract documents and Top antibiotics deals by value are provided in this research. The Antibiotics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering: Antibiotics, Aminoglycosides, Cephalosporin, Clindamycin, Macrolides, Penicillin, Quinolones, Sulfonamides and Tetracycline. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

These reports contains over 150 links (antibiotics report) and 1000 links (personalized medicine partnering terms report) to online copies of actual antibiotics and personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements helps answering questions like what is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?

Order a copy of Personalized Medicine Partnering Terms and Agreements report at http://www.rnrmarketresearch.com/contacts/purchase?rname=61648 and the Antibiotics Partnering Terms and Agreements report is available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=94305.

The initial chapters of these reports provide an orientation of antibiotics and personalized medicine deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine and antibiotics deal making since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announced along with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009 organized by antibiotics technology focus. The chapter includes deals listed by antibiotics and broken down into individual type of antibiotics- aminoglycosides, cephalosporin, clindamycin, macrolides, metronidazole, penicillin, quinolones and tetracycline. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z , stage of development, deal type and therapy focus, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Explore more reports on pharmaceuticals markets and other newly published research on overall healthcare industry at http://www.rnrmarketresearch.com/reports/life-sciences/healthcare .

About Us:
RnRMarketResearch.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.

Contact:  

Ritesh Tiwari / Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441

sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research